TVRD

#4507
Tvardi Therapeutics, Inc. - Common Stock
1.7 5 USD
-0.03%
Market Price
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
1.75
1.75
Range Annuel
1.50
5.69
Changement quotidien
-2.78%
Changement Mensuel
-16.27%
Evolution sur 6 mois
-54.90%
Changement Annuel
-51.39%
Clôture Précédente
1.8 0
Open
1.7 5
Low
1.7 5
High
1.7 5
Volume
5
Afficher le graphique complet

Financials

Aperçu Relevé Statistiques Documents

2026

Current report, Q3 FY2026
Tvardi Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Tvardi Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Tvardi Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Tvardi Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Tvardi Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Tvardi Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Tvardi Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Tvardi Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Tvardi Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Tvardi Therapeutics, Inc. current report, Q1 FY2026
8-K

Tvardi Therapeutics, Inc. current report, 04 June 2020

Full document

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Stockholders held by Cara Therapeutics, Inc. on June 4, 2020. The filing details the voting results for four proposals submitted to security holders. Note: The request metadata references "Tvardi Therapeutics, Inc.," but the filing text explicitly identifies the registrant as "Cara Therapeutics, Inc."

Key Financial Metrics

This filing is a Current Report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.

Material Changes and Voting Results

The following proposals were voted upon at the Annual Meeting:

  • Proposal 1 (Election of Directors): Dr. Derek Chalmers and Mr. Martin Vogelbaum were elected to the Board of Directors until the 2023 Annual Meeting.
    • Derek Chalmers: 26,860,226 votes For; 320,733 votes Withheld.
    • Martin Vogelbaum: 16,757,430 votes For; 10,423,529 votes Withheld.
  • Proposal 2 (Executive Compensation): Stockholders approved the compensation of Named Executive Officers on a non-binding advisory basis.
    • Result: 26,434,667 votes For; 480,766 votes Against.
  • Proposal 3 (Frequency of Say-on-Pay): Stockholders approved holding future advisory votes on executive compensation every year.
    • Result: 26,880,583 votes for 1 Year; 103,111 votes for 2 Years; 127,459 votes for 3 Years.
  • Proposal 4 (Auditor Ratification): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2020.
    • Result: 39,324,718 votes For; 204,726 votes Against.

Guidance, Outlook, and Risks

This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the outcomes of the shareholder vote.

Investor Verification Checklist

  • Verify the company name discrepancy between the request metadata ("Tvardi Therapeutics") and the filing ("Cara Therapeutics").
  • Review the Proxy Statement filed on April 22, 2020, for detailed descriptions of the director nominees and executive compensation packages.
  • Confirm the tenure of the newly elected directors (Dr. Chalmers and Mr. Vogelbaum) extends through the 2023 Annual Meeting.
  • Note the significant number of broker non-votes (12,405,182) recorded across all proposals.